Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPLSG-ALL-B19 phase III study in newly diagnosed B-cell precursor acute lymphoblastic leukemia
jRCTs041210040Phase 3Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2021
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of blinatumomab, mercaptopurine and Asparaginase erwinia chrysanthemi in acute lymphoblastic leukemia (ALL) (7 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Five-year event-free survival in RCT-LR, Five-year event-free survival in RCT-HR and 2 more. Started Jul 2021; status: recruiting.
02
Drugs
blinatumomabmercaptopurineAsparaginase erwinia chrysanthemi
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041210040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210040.